Senolytics

What the evidence says

Senescent cells stop dividing and can release signals that affect surrounding tissue. Senolytics are intended to selectively remove some of these cells, but different compounds and combinations are not interchangeable and the human program remains at an early translational stage.^[2]

A randomized pilot of dasatinib plus quercetin enrolled only 12 people with idiopathic pulmonary fibrosis. It was designed to assess feasibility and tolerability, not efficacy; exploratory frailty, lung, and physical-function measures did not appear meaningfully different between groups.^[1]

An open-label study in nine people with diabetic kidney disease reported reduced markers of senescent-cell burden after three treatment days. A separate open-label phase 1 study in five people with mild Alzheimer disease established limited central nervous system exposure to dasatinib but found no significant change in cognitive or imaging outcomes.^[2][4]

The largest published trial is still small: in 60 postmenopausal women, intermittent dasatinib plus quercetin did not improve the primary bone-resorption endpoint overall. Short-lived secondary biomarker changes and exploratory subgroup findings are hypotheses, not established clinical benefit.^[3]

Dasatinib is an oncology medicine whose prescribing information warns about myelosuppression, serious bleeding, fluid retention, cardiovascular effects, pulmonary hypertension, and drug interactions. Tiny intermittent-dose studies cannot rule out uncommon or cumulative harms in people without cancer.^[5]